U.S. markets open in 9 hours 20 minutes
  • S&P Futures

    3,931.00
    +8.50 (+0.22%)
     
  • Dow Futures

    32,018.00
    +102.00 (+0.32%)
     
  • Nasdaq Futures

    13,328.50
    +26.50 (+0.20%)
     
  • Russell 2000 Futures

    2,300.00
    +14.90 (+0.65%)
     
  • Crude Oil

    63.10
    -0.12 (-0.19%)
     
  • Gold

    1,796.80
    -1.10 (-0.06%)
     
  • Silver

    28.07
    +0.21 (+0.76%)
     
  • EUR/USD

    1.2183
    +0.0015 (+0.12%)
     
  • 10-Yr Bond

    1.3890
    +0.0270 (+1.98%)
     
  • Vix

    21.34
    -1.77 (-7.66%)
     
  • GBP/USD

    1.4163
    +0.0021 (+0.15%)
     
  • USD/JPY

    105.8740
    -0.0080 (-0.01%)
     
  • BTC-USD

    49,817.88
    -1,305.03 (-2.55%)
     
  • CMC Crypto 200

    995.13
    -19.79 (-1.95%)
     
  • FTSE 100

    6,658.97
    +33.03 (+0.50%)
     
  • Nikkei 225

    30,124.88
    +453.18 (+1.53%)
     

Cara Therapeutics to Present at the Jefferies 2019 Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

STAMFORD, Conn., May 31, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on pruritus by selectively targeting peripheral kappa opioid receptors, today announced a Company presentation at the Jefferies 2019 Healthcare Conference on Wednesday, June 5, 2019 at 9:30 a.m. ET in New York, NY.

A live webcast of the presentation can be accessed under "Events & Presentations" in the News & Investors section of the Company's website at www.CaraTherapeutics.com. An archived webcast recording will be available on the Cara website for approximately 30 days.

About Cara Therapeutics

Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Cara is developing a novel and proprietary class of product candidates, led by KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist that targets the body's peripheral nervous system, as well as certain immune cells. In a Phase 3 trial and Phase 2 trials, KORSUVA injection has demonstrated statistically significant reductions in itch intensity and concomitant improvement in quality of life measures in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP), and is currently being investigated in Phase 3 trials in hemodialysis patients with CKD-aP.

The FDA has conditionally accepted KORSUVA™ as the trade name for difelikefalin injection. CR845/difelikefalin is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority.

INVESTOR CONTACT:
Michael Schaffzin
Stern Investor Relations, Inc.
212-362-1200
michael.schaffzin@sternir.com

MEDIA CONTACT:
Annie Starr
6 Degrees
973-415-8838
astarr@6degreespr.com